Equities

Neurocrine Biosciences Inc

Neurocrine Biosciences Inc

Actions
  • Price (USD)125.56
  • Today's Change0.640 / 0.51%
  • Shares traded613.00
  • 1 Year change+8.40%
  • Beta--
Data delayed at least 20 minutes, as of Nov 08 2024 18:58 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments1,032989711
Total Receivables, Net439350186
Total Inventory383531
Prepaid expenses------
Other current assets, total987946
Total current assets1,6071,454973
Property, plant & equipment, net347146156
Goodwill, net------
Intangibles, net3637--
Long term investments849402624
Note receivable - long term------
Other long term assets50254.40
Total assets3,2512,3692,073
LIABILITIES
Accounts payable------
Accrued expenses163129100
Notes payable/short-term debt000
Current portion long-term debt/capital leases170169--
Other current liabilities, total3.903.303.50
Total current liabilities655538246
Total long term debt00335
Total debt170169335
Deferred income tax------
Minority interest------
Other liabilities, total365123118
Total liabilities1,019661699
SHAREHOLDERS EQUITY
Common stock0.100.100.10
Additional paid-in capital2,3822,1222,011
Retained earnings (accumulated deficit)(157)(407)(636)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total7.00(7.9)(1.7)
Total equity2,2321,7081,374
Total liabilities & shareholders' equity3,2512,3692,073
Total common shares outstanding999795
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.